Eli Lilly blows past estimates, hikes guidance as Zepbound and Mounjaro sales soar - CNBC


10/30/2025

Eli Lilly blows past estimates, hikes guidance as Zepbound and Mounjaro sales soar  CNBCObesity, diabetes treatments fuel Eli Lilly growth and spark bidding war  Yahoo FinanceEli Lilly raises forecasts on surging international demand for weight-loss drugs  ReutersLilly's Zepbound, Mounjaro show out with $10B quarter despite CVS formulary hitch  Fierce PharmaEli Lilly Stock Rises on Earnings and Boost to Guidance  Barron's...

Original

Tags: as | cnbc | earnings | for | guidance | international | raises | rises | sales | show | stock | to | with



Let us know what you think!

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

Leave a Comment

Scroll back to top